ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1036

The Spectrum of the Biopsy-Proven Glomerular Disease in Taiwan: A Single-Center Experience

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Sun, Wei chiao, Chang Gung Memorial Hospital, Taoyuan, Taiwan
  • Chen, Tai-Di, Chang Gung Memorial Hospital, Taoyuan, Taiwan
  • Lee, Cheng chia, Chang Gung Memorial Hospital, Taoyuan, Taiwan
  • Chang, Chih-Hsiang, Chang Gung Memorial Hospital, Taoyuan, Taiwan
  • Tu, Kun-Hua, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Glomerular diseases are still leading causes of end-stage renal disease. The diagnosis of these disease relies on the interpretation of the renal biopsy. The sonography-guided biopsy is still the major tool to acquire an accurate pathologic diagnosis. The spectrums of the glomerular disease are varied in different regions. Grossly, IgA nephropathy is the leading cause of primary glomerular disease in Asia. To date, there are few articles which report the disease spectrum in Taiwan. This study conducts a retrospective investigation of 19-years cohorts in a single medical center. The trend of disease spectrum was evaluated and analyzed.


This investigation was performed in a tertiary hospital. From 2000-2018 period, totally 2,391 patients first received renal biopsy. After excluding 71 cases of tubulointerstitial disease, 270 cases of end-stage renal disease, advanced chronic kidney disease, inadequate sampling, and failed interpretation, there are still 2,050 cases with a clear diagnosis.


Membranous glomerulopathy is the leading category in 2,050 cases (404, 19.7%), followed by IgA nephropathy (306 cases, 14.9%), minimal change nephropathy (283, 13.8%), focal segmental glomerulosclerosis (180, 8.8%). In the secondary disease, lupus nephritis account for 18.4% of the 2050 cases (378), followed by diabetic nephropathy (200, 9.6%), and paraproteinemic renal disease (60, 2.9%). Notably, the incidence of the membranous glomerulopathy is decreasing by year. In contrast, the ratios of IgA nephropathy is increasing gradually.


Membranous glomerulopathy is the major category in 19-years cohort of a single medical center, although the incidence is decreasing by year. Further investigation of change of disease spectrum is necessary.